More Byetta Deaths Reported After FDA Announcement

2008-09-02 17:58:46 (GMT) (Caymanmama.com - Featured Law News)



September 1, 2008- Reports were released regarding the deaths of four more individuals who used the drug Byetta, approximately one week after the Food and Drug Administration announced the deaths of two people who developed pancreatitis, which may be linked to taking the drug. Manufactured by Amylin Pharmaceuticals Inc., Byetta is used to treat Type 2 diabetes.

Pancreatitis was said to be a possible issue in all six deaths, with the four most recently reported having milder forms. Thirty other reports of the condition in users of Byetta have been acknowledged by the FDA. Rival medications have also been reported to produce similar issues for patients. Symptoms of pancreatitis include abdominal pain, vomiting, nausea, and other health complications. The patients who were the subject of the report were also stated to all have other medical problems in addition to diabetes which probably significantly contributed to their deaths.

Byetta has not yet been proven to be a cause of pancreatitis; however the incidence of the disease in the death cases has led to plans for a comprehensive review and additional research on the drug. The FDA has also stated that better labeling for Byetta is in the works. The injected medication was approved in 2005, and is said to have been used by over 700,000 people to date.

The Food and Drug Administration can provide individuals with more information on Byetta and other potentially dangerous drugs. Those who experience symptoms of pancreatitis, or other health complications after taking any medication are advised to stop taking it immediately, and seek the proper medical attention.

Those seeking legal help can contact a personal injury lawyer.
Contributor:  Eberstein & Witherite, LLP a Dallas personal injury law firm with a combined 40 years of legal practice working for injured Texas clients.



CaymanMama.com - Press Release Distribution Service

Comments

Comments are closed.



Articles